The analytical validation utilizing Epic Sciences' liquid biopsy CTC platform demonstrated the potential to detect PSMA protein expression in CTCs from patients with mCRPC. This assay is positioned as an effective research tool to evaluate PSMA expression, heterogeneity, and therapeutic response in many ongoing clinical studies to target tumors that express PSMA.
Keyphrases
- circulating tumor cells
- pet ct
- pet imaging
- prostate cancer
- poor prognosis
- circulating tumor
- high throughput
- positron emission tomography
- ultrasound guided
- binding protein
- ionic liquid
- fine needle aspiration
- radical prostatectomy
- single cell
- loop mediated isothermal amplification
- computed tomography
- climate change
- liquid chromatography
- human health
- mass spectrometry
- label free